The promise and limitations of anti-inflammatory agents for the treatment of major depressive disorder

Research output: Chapter in Book/Report/Conference proceedingChapter

11 Citations (Scopus)

Abstract

This review provides a critical perspective on recent meta-analyses suggesting that several anti-inflammatory modalities, including nonsteroidal anti inflammatory drugs (NSAIDs), omega-3 fatty acids, and cytokine antagonist, possess generalizable antidepressant properties. By examining confounds and limitations in the available literature it is suggested that current data suggest that only a sub-group of individuals with major depressive disorder (MDD) have evidence of increased inflammatory biomarkers and it is in these individuals that anti inflammatory agents show promise for reducing depressive symptoms. The treatment implications of this cautionary perspective are discussed.

Original languageEnglish (US)
Title of host publicationCurrent Topics in Behavioral Neurosciences
PublisherSpringer Verlag
Pages287-302
Number of pages16
Volume31
DOIs
StatePublished - 2017
Externally publishedYes

Publication series

NameCurrent Topics in Behavioral Neurosciences
Volume31
ISSN (Print)1866-3370
ISSN (Electronic)1866-3389

Fingerprint

Major Depressive Disorder
Anti-Inflammatory Agents
Omega-3 Fatty Acids
Antidepressive Agents
Meta-Analysis
Biomarkers
Depression
Cytokines
Pharmaceutical Preparations

Keywords

  • Antidepressants
  • Cytokine antagonists
  • Cytokines
  • Inflammation
  • Major depressive disorder
  • Nonsteroidal anti-inflammatory drugs
  • Omega-3 fatty acids

ASJC Scopus subject areas

  • Medicine(all)
  • Behavioral Neuroscience

Cite this

Raison, C. L. (2017). The promise and limitations of anti-inflammatory agents for the treatment of major depressive disorder. In Current Topics in Behavioral Neurosciences (Vol. 31, pp. 287-302). (Current Topics in Behavioral Neurosciences; Vol. 31). Springer Verlag. https://doi.org/10.1007/7854_2016_26

The promise and limitations of anti-inflammatory agents for the treatment of major depressive disorder. / Raison, Charles L.

Current Topics in Behavioral Neurosciences. Vol. 31 Springer Verlag, 2017. p. 287-302 (Current Topics in Behavioral Neurosciences; Vol. 31).

Research output: Chapter in Book/Report/Conference proceedingChapter

Raison, CL 2017, The promise and limitations of anti-inflammatory agents for the treatment of major depressive disorder. in Current Topics in Behavioral Neurosciences. vol. 31, Current Topics in Behavioral Neurosciences, vol. 31, Springer Verlag, pp. 287-302. https://doi.org/10.1007/7854_2016_26
Raison CL. The promise and limitations of anti-inflammatory agents for the treatment of major depressive disorder. In Current Topics in Behavioral Neurosciences. Vol. 31. Springer Verlag. 2017. p. 287-302. (Current Topics in Behavioral Neurosciences). https://doi.org/10.1007/7854_2016_26
Raison, Charles L. / The promise and limitations of anti-inflammatory agents for the treatment of major depressive disorder. Current Topics in Behavioral Neurosciences. Vol. 31 Springer Verlag, 2017. pp. 287-302 (Current Topics in Behavioral Neurosciences).
@inbook{9918959a4f0644f989e3cf81b11804ee,
title = "The promise and limitations of anti-inflammatory agents for the treatment of major depressive disorder",
abstract = "This review provides a critical perspective on recent meta-analyses suggesting that several anti-inflammatory modalities, including nonsteroidal anti inflammatory drugs (NSAIDs), omega-3 fatty acids, and cytokine antagonist, possess generalizable antidepressant properties. By examining confounds and limitations in the available literature it is suggested that current data suggest that only a sub-group of individuals with major depressive disorder (MDD) have evidence of increased inflammatory biomarkers and it is in these individuals that anti inflammatory agents show promise for reducing depressive symptoms. The treatment implications of this cautionary perspective are discussed.",
keywords = "Antidepressants, Cytokine antagonists, Cytokines, Inflammation, Major depressive disorder, Nonsteroidal anti-inflammatory drugs, Omega-3 fatty acids",
author = "Raison, {Charles L}",
year = "2017",
doi = "10.1007/7854_2016_26",
language = "English (US)",
volume = "31",
series = "Current Topics in Behavioral Neurosciences",
publisher = "Springer Verlag",
pages = "287--302",
booktitle = "Current Topics in Behavioral Neurosciences",
address = "Germany",

}

TY - CHAP

T1 - The promise and limitations of anti-inflammatory agents for the treatment of major depressive disorder

AU - Raison, Charles L

PY - 2017

Y1 - 2017

N2 - This review provides a critical perspective on recent meta-analyses suggesting that several anti-inflammatory modalities, including nonsteroidal anti inflammatory drugs (NSAIDs), omega-3 fatty acids, and cytokine antagonist, possess generalizable antidepressant properties. By examining confounds and limitations in the available literature it is suggested that current data suggest that only a sub-group of individuals with major depressive disorder (MDD) have evidence of increased inflammatory biomarkers and it is in these individuals that anti inflammatory agents show promise for reducing depressive symptoms. The treatment implications of this cautionary perspective are discussed.

AB - This review provides a critical perspective on recent meta-analyses suggesting that several anti-inflammatory modalities, including nonsteroidal anti inflammatory drugs (NSAIDs), omega-3 fatty acids, and cytokine antagonist, possess generalizable antidepressant properties. By examining confounds and limitations in the available literature it is suggested that current data suggest that only a sub-group of individuals with major depressive disorder (MDD) have evidence of increased inflammatory biomarkers and it is in these individuals that anti inflammatory agents show promise for reducing depressive symptoms. The treatment implications of this cautionary perspective are discussed.

KW - Antidepressants

KW - Cytokine antagonists

KW - Cytokines

KW - Inflammation

KW - Major depressive disorder

KW - Nonsteroidal anti-inflammatory drugs

KW - Omega-3 fatty acids

UR - http://www.scopus.com/inward/record.url?scp=85007524853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007524853&partnerID=8YFLogxK

U2 - 10.1007/7854_2016_26

DO - 10.1007/7854_2016_26

M3 - Chapter

C2 - 27278642

AN - SCOPUS:85007524853

VL - 31

T3 - Current Topics in Behavioral Neurosciences

SP - 287

EP - 302

BT - Current Topics in Behavioral Neurosciences

PB - Springer Verlag

ER -